The FDA on December 18, 2020 approved XPOVIO® in combination with VELCADE® (Bortezomib) and Dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. XPOVIO® is a product of Karyopharm Therapeutics Inc.
Bottom Ad
Advertisement
Subscribe
